Trishula Therapeutics has reported encouraging initial data from an ongoing Phase I trial of its anti-CD39 antibody TTX-030 with budigalimab (investigational anti-PD-1) and FOLFOX for gastric cancer.
SOUTH SAN FRANCISCO, Calif., April 4, 2022 /PRNewswire/ -- Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class anti-CD39 antibody in advanced cancers, today announced preliminary results from an ongoing Phase 1 trial evaluating TTX-030 in combination with chemoimmunotherapy for the first-line treatment of patients with locally advanced or metastatic HER2- gastric or gastroesophageal junction (GEJ) cancer will be highlighted in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, LA, April 8-13, 2022.
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Today Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class anti-CD39 antibody in advanced cancers, announced the appointment of Anil Singhal, Ph.D., MBA, as Chief Executive Officer, effective immediately. Dr. Singhal will also serve on the Trishula Board of Directors.